Clinical Trials Overview GCP comparison History · Evolution Current 2026 Future 2026-2035 AI lens Flow of trials Players & stakeholders Signals

Library/Clinical Trials/History · Evolution

chapter 03 · the regulatory arc

History & evolution: from Reed to E6(R3).

Modern clinical trial regulation is the residue of scandal answered by ethics answered by codification. Seven eras — pre-regulatory through AI/ML-augmented adaptive.

/ 06

History: from Reed to E6(R3).

Origin events · 1900–2024

Modern clinical trial regulation is the residue of scandal answered by ethics answered by codification. Each line in the timeline below is a moment where the conduct of research on human beings shifted from investigator conscience to written, enforceable rule.

1900

Walter Reed yellow fever protocol (Cuba) — the U.S. Army Yellow Fever Commission used early written informed-consent contracts in English and Spanish, signed by volunteers with witnesses, acknowledging risk of death and offering monetary compensation. Pre-dates Nuremberg by ~47 years; isolated investigator practice, not regulatory norm. Specific archival details to be cited from Walter Reed Army Institute archives.

1932–1972

Tuskegee Syphilis Study (USPHS) — "The study initially involved 600 Black men — 399 with syphilis, 201 who did not have the disease" (CDC). Informed consent was not obtained; investigators actively prevented penicillin access from 1947. Peter Buxtun's whistleblower disclosure → Jean Heller AP wire story (July 1972) terminated the study. The scandal that produced the National Research Act.

1947 · Aug

Nuremberg Code (U.S. v. Karl Brandt et al., Military Tribunal I — the "Doctors' Trial"). 23 defendants tried; 16 found guilty, 7 sentenced to death and executed 2 June 1948. Ten-point verdict rationale on permissible medical experiments; foundational sentence: "the voluntary consent of the human subject is absolutely essential". Pure ethical scaffold; no operational specificity.

1962 · Oct 10

Kefauver-Harris Drug Amendments (US Public Law 87-781, signed 10 October 1962) — response to thalidomide. Strengthened requirements for proof of safety and effectiveness and required informed consent for drug trial participants. Birth of the modern clinical trial as registration requirement; parent of 21 CFR 312. (Thalidomide-affected birth-defect totals are epidemiologic estimates from secondary literature.)

1964 · June

Declaration of Helsinki (WMA 18th General Assembly, Helsinki, June 1964) — therapeutic vs. non-therapeutic distinction; ethics committee protocol review; physician duty to put participant welfare above science. Successive revisions through 2013; the most recent revision was adopted at the WMA 75th General Assembly (October 2024).

1974 · Jul 12

National Research Act (US Public Law 93-348, signed 12 July 1974) — mandated IRBs for federally-funded research; established the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research that would publish Belmont.

1979 · Apr 18

Belmont Report (HHS / OHRP, 18 April 1979) — three basic ethical principles: respect for persons, beneficence, justice. Philosophical scaffold for 45 CFR 46 and 21 CFR 50 / 56.

1981 · Jan 27

21 CFR 50 (Protection of Human Subjects) + 21 CFR 56 (IRBs) — codified Belmont principles into US regulation; original FR citation includes 46 FR 8942 (27 January 1981). Subpart D (Additional Safeguards for Children) implemented later via rulemaking finalised at 66 FR 20589 (24 April 2001).

1987

21 CFR 312 IND Rewrite — modern investigational drug application framework. Interlocks with 21 CFR 4 (combination-product cGMP, 2013) and 21 CFR 812 (IDE).

1996 · Jun 10

ICH E6(R1) Good Clinical Practice reached Step 4, current Step 4 version dated 10 June 1996. First global GCP harmonisation. The Protocol / IB / CRF triad and TMF structure every CRO SOP descends from. (Specific "principle / requirement / responsibility" counts vary in interpretation; use the Step 4 PDF for canonical figures.)

2001 · Apr 4

EU Clinical Trials Directive 2001/20/EC (4 April 2001; OJ L 121, 1 May 2001) — attempted EU harmonisation; produced 27 Member States → 27 implementations. Subsequent Commission impact-assessment commentary noted significant declines in EU clinical-trial application volumes; specific percentages should be cited from the Commission impact assessments rather than treated as primary statute facts.

2016 · Nov 9

ICH E6(R2) integrated addendum reached Step 4 — current Step 4 version dated 9 November 2016. Risk-based quality management, sponsor vendor oversight, electronic records, CAPA for deviations. Acknowledged EDC-era reality.

2019 · Mar 19

India NDCT Rules 2019 (Gazette of India G.S.R. 227(E), 19 March 2019) — superseded Schedule Y. Compulsory compensation for CT-related injury, orphan-drug recognition, academic-trial framework, 30 / 90-day CDSCO timelines.

2020 · Mar 18

FDA Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency (first issued 18 March 2020) — remote consent, direct-to-participant IMP, telemedicine visits, decentralised source data became operational within months. A decade of debate compressed.

2022 · Jan 31

EU CTR 536/2014 goes live (CTIS portal) — single submission, single Reporting Member State assessment (Part I), parallel national (Part II); protocol, lay-summary, and results-disclosure obligations apply under the current EU CTR framework. Transition window for legacy Directive 2001/20/EC trials closed 31 January 2025.

2022 · Dec 29

FDORA (Food and Drug Omnibus Reform Act of 2022, enacted as Division FF of the Consolidated Appropriations Act, 2023; US Public Law 117-328, signed 29 December 2022) — Section 3602 added Diversity Action Plan provisions. FDA Modernization Act 2.0 (US Public Law 117-286, signed 29 December 2022 as separate legislation) removed the explicit animal-testing requirement from FFDCA §505.

2024 · May

Brazil Lei 14.874/2024 (Marco Legal das Pesquisas Clínicas) — sanctioned May 2024. ANVISA RDC 945/2024 provides implementing regulation. Specific Diário Oficial da União dates and operational provisions to be cited from the official text.

2025 · Jan 6

ICH E6(R3) Step 4 (6 January 2025) — structural rewrite, not addendum. Articulates a revised set of overarching GCP principles in the Step 4 text; Annex 1 (interventional), Annex 2 (non-traditional designs, in development). Quality-by-design from protocol inception; participant-centric language. FDA / EMA implementation guidance through 2025–2026.

/ 07

Evolution: seven eras of clinical-trial regulation.

scandal → ethics → codification

The same arc, viewed as eras rather than dates. Each era is defined by the failure or scandal that forced new ethical scaffolding, and the codification that followed.

Era 1 · pre-1947

Pre-regulatory: investigator conscience.

Walter Reed (1900) used written, bilingual, witnessed consent contracts in Cuba — isolated practice, not norm. The Tuskegee study (1932–1972) ran without informed consent, exposing the gap that would eventually force codification.

Era 2 · 1947–1962

Ethical scaffolds: Nuremberg to thalidomide.

The Nuremberg Code (1947) established voluntary consent as foundational principle but had no operational specificity. Thalidomide forced Kefauver-Harris (1962) — the first US statute requiring proof of effectiveness alongside safety.

Era 3 · 1964–1979

Codification: Helsinki, Belmont, IRB.

Declaration of Helsinki (1964) and Belmont Report (1979) gave the discipline its philosophical scaffold. The National Research Act (1974) created the IRB requirement that would become 21 CFR 50 / 56 in 1981.

Era 4 · 1981–1996

Statutory framework: CFR and ICH-GCP.

21 CFR 50 / 56 (1981) and the IND rewrite (1987) gave the US its regulatory architecture. ICH E6(R1) (1996) was the first global GCP harmonisation; the Protocol / IB / CRF triad every CRO SOP descends from.

Era 5 · 2001–2016

Harmonisation strain: EU Directive to E6(R2).

EU CT Directive 2001/20/EC produced 27 implementations; the EU clinical-trial environment became less competitive. ICH E6(R2) (2016) was an addendum acknowledging EDC-era reality — not a rewrite.

Era 6 · 2019–2024

Decentralisation: COVID compresses a decade.

India NDCT Rules (2019) replaced Schedule Y. FDA's COVID guidance (March 2020) made decentralised conduct operational. EU CTR (2022) replaced the Directive. FDORA (2022) added Diversity Action Plans.

Era 7 · 2025–

Principles-based: E6(R3) and beyond.

ICH E6(R3) (Step 4, 6 January 2025) is a structural rewrite. Quality-by-design from protocol inception, participant-centric language, room for non-traditional designs (Annex 2 in development). Implementation rolling across regions through 2025–2026.

/ SRC

Official source register.

GCP / trial conduct anchors

ICH E6(R3)

Good Clinical Practice Step 4.

Official ICH E6(R3) Step 4 guideline. Use as the primary GCP anchor for participant protection, quality-by-design, sponsor oversight, and proportionality.

PDF ↗

ICH E8(R1)

General considerations for clinical studies.

Official ICH E8(R1) guideline. Use for quality-by-design and critical-to-quality thinking before trial execution begins.

PDF ↗

ICH E9(R1)

Estimands and sensitivity analysis.

Official ICH E9(R1) addendum. Use for aligning trial objectives, intercurrent events, estimands, and statistical interpretation.

PDF ↗

ICH M11

Clinical electronic structured harmonised protocol.

Official FDA-hosted ICH M11 page. Use for structured protocol thinking and protocol information that can become more reusable across systems.

official ↗

FDA DCT

Clinical trials with decentralized elements.

FDA guidance page for decentralized trial elements. Use for remote visits, local healthcare providers, direct-to-participant processes, and oversight expectations.

official ↗

FDA DAP